Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Proteon Thera Com ST (PRTO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Proteon Therapeutics to Present at the Baird 2017 Global Healthcare Conference September 7, 2017

Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced that Company...

PRTO : 2.25 (-2.17%)
Proteon Therapeutics Announces Second Quarter 2017 Financial Results

Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced financial results...

PRTO : 2.25 (-2.17%)
Proteon Therapeutics Announces $22.0 Million Private Placement

Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced that it has...

PRTO : 2.25 (-2.17%)
Proteon Therapeutics to Present at the JMP Securities Life Sciences Conference June 21st

Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced that Company...

PRTO : 2.25 (-2.17%)
Proteon Therapeutics Announces Increase to Enrollment of Ongoing Phase 3 PATENCY-2 Clinical Trial

Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced that it will...

PRTO : 2.25 (-2.17%)
Proteon Therapeutics to Present at the Deutsche Bank 42nd Annual Health Care Conference May 4th

Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced that Company...

PRTO : 2.25 (-2.17%)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Proteon Therapeutics, Inc.

Levi & Korsinsky announces it has commenced an investigation of Proteon Therapeutics, Inc. (NASDAQ:PRTO) concerning possible violations of federal securities laws. The investigation concerns...

PRTO : 2.25 (-2.17%)
Proteon Therapeutics to Present at the Oppenheimer 27th Annual Healthcare Conference March 22nd

Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced that Company...

PRTO : 2.25 (-2.17%)
Proteon Therapeutics Announces Full-Year 2016 Financial Results and Changes to the Ongoing Phase 3 PATENCY-2 Clinical Trial

- Efficacy endpoints reordered and co-primary endpoints established -

PRTO : 2.25 (-2.17%)
Proteon Slips to 52-Week Low on Kidney Disease Study Data

Proteon's (PRTO) shares hit a 52-week low after reporting poor top-line phase III data on vonapanitase in patients with chronic kidney disease.

SCMP : 10.30 (+0.49%)
PRTO : 2.25 (-2.17%)
VNDA : 16.00 (unch)
MNKD : 4.11 (+3.79%)

Van Meerten Stock Picks

My 5 Favorite NASDAQ 100 Stocks
This morning I wanted to find the 5 best NASDAQ 100 stocks that had the highest return in the past year, had consistent price appreciation and still looked like they had room to go.
AMAT +0.76 , NVDA -0.90 , ADSK +1.52 , MU +0.19 , LRCX +4.36
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

Barchart Morning Call

OVERNIGHT MARKETS AND NEWS Dec E-mini S&Ps ( ESZ17 +0.21%) this morning are up +0.23% at a new record high on optimism that the Trump administration will be able to enact its tax reform plans after the Senate adopted a fiscal 2018 budget... Read More

Chart of the Day

Chart of the Day

LimeLight Networks (LLNW) is the Barchart Chart of the Day.  The Internet company has a Trend Spotter buy signal, a Weighted Alpha of 18.33+ and gained 149.71% in the last year.
Read More

Brugler Ag Report

Today's Commentary

Corn futures ended Friday with most contracts 3 1/2 to 4 1/2 cents lower. The USDA announced private export sales of 125,000 MT of corn to Unknown Destinations, with an additional 120,000 MT to Spain for 17/18 delivery through their daily reporting s...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart